- Home
- APPN vs CNTA Comparison
APPN vs CNTA Comparison
Compare APPN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPN
- CNTA
- Stock Information
- Founded
- APPN 1999
- CNTA 2020
- Country
- APPN United States
- CNTA United Kingdom
- Employees
- APPN N/A
- CNTA N/A
- Industry
- APPN Computer Software: Prepackaged Software
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- APPN Technology
- CNTA Health Care
- Exchange
- APPN Nasdaq
- CNTA Nasdaq
- Market Cap
- APPN 2.8B
- CNTA 2.3B
- IPO Year
- APPN 2017
- CNTA 2021
- Fundamental
- Price
- APPN $33.89
- CNTA $17.01
- Analyst Decision
- APPN Hold
- CNTA Strong Buy
- Analyst Count
- APPN 5
- CNTA 7
- Target Price
- APPN $40.75
- CNTA $23.71
- AVG Volume (30 Days)
- APPN 359.6K
- CNTA 606.1K
- Earning Date
- APPN 02-13-2025
- CNTA 11-12-2024
- Dividend Yield
- APPN N/A
- CNTA N/A
- EPS Growth
- APPN N/A
- CNTA N/A
- EPS
- APPN N/A
- CNTA N/A
- Revenue
- APPN $595,656,000.00
- CNTA $6,853,000.00
- Revenue This Year
- APPN $14.96
- CNTA N/A
- Revenue Next Year
- APPN $11.19
- CNTA N/A
- P/E Ratio
- APPN N/A
- CNTA N/A
- Revenue Growth
- APPN 13.28
- CNTA N/A
- 52 Week Low
- APPN $26.28
- CNTA $6.65
- 52 Week High
- APPN $43.33
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- APPN 40.78
- CNTA 49.87
- Support Level
- APPN $32.21
- CNTA $15.45
- Resistance Level
- APPN $34.97
- CNTA $18.00
- Average True Range (ATR)
- APPN 1.35
- CNTA 1.17
- MACD
- APPN -0.34
- CNTA -0.04
- Stochastic Oscillator
- APPN 26.65
- CNTA 58.43
About APPN Appian Corporation
Appian is a low-code enterprise platform-as-a-service company focusing on business process management. The Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. Most of Appian's revenue is subscription based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform, Appian Cloud.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.